About The Study: Among metabolic and bariatric surgery (MBS)-eligible patients in a national sample, semaglutide and tirzepatide prescriptions increased dramatically between 2018 and 2025, whereas MBS use rates declined substantially beginning in 2023. Stratification by procedure type and body mass index (BMI) category suggests that recent shifts in MBS use may be more pronounced in certain patient subgroups (e.g., those seeking sleeve gastrectomy or with lower BMIs).
Corresponding Author: To contact the corresponding author, Stefanie C. Rohde, MD, email stefanie.rohde@osumc.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamasurg.2026.0049)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2026.0049?guestAccessKey=115d5941-818f-4bc4-a1b0-de10818b7e13&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=030426
JAMA Surgery